APA (7th ed.) Citation

Frost, N., Christopoulos, P., Kauffmann-Guerrero, D., Stratmann, J., Riedel, R., Schaefer, M., . . . Griesinger, F. (2021). Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: Results from the German early access program. Therapeutic advances in medical oncology, 13, . https://doi.org/10.1177/1758835920980558

Chicago Style (17th ed.) Citation

Frost, Nikolaj, et al. "Lorlatinib in Pretreated ALK- or ROS1-positive Lung Cancer and Impact of TP53 Co-mutations: Results from the German Early Access Program." Therapeutic Advances in Medical Oncology 13 (2021). https://doi.org/10.1177/1758835920980558.

MLA (9th ed.) Citation

Frost, Nikolaj, et al. "Lorlatinib in Pretreated ALK- or ROS1-positive Lung Cancer and Impact of TP53 Co-mutations: Results from the German Early Access Program." Therapeutic Advances in Medical Oncology, vol. 13, 2021, https://doi.org/10.1177/1758835920980558.